Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetes

Practical Diabetes International

Volumn 21, Issue 3, 2004, Pages 110-114

  Gallen, Ian ^a   Carter, C ^a  

^a WYCOMBE HOSPITAL   (United Kingdom)

Author keywords

Insulin glargine; Nocturnal hypoglycaemia; Patient satisfaction surveys; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE SEVERITY; DRUG INDICATION; ERECTILE DYSFUNCTION; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL AUDIT; MEDICAL DOCUMENTATION; PATIENT ATTITUDE; PATIENT MONITORING; PATIENT SATISFACTION; PATIENT SELECTION; PHYSICAL CAPACITY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; WELLBEING;

EID: 2342420835     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.604     Document Type: Article

References (17)

1. The Diabetes Control and Complications (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-independent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. National Institute for Clinical Excellence. Technology Appraisal Guidance - No. 53. Guidance on the Use of Long-Acting Insulin Analogues for Treatment of Diabetes - Insulin Glargine. London: NICE, 2002.
3. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2124-2148.
4. Pieber TR, Eugene-Jolchine I, Derobert E, The European Study Group of HOE 901 in Type 1 Diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000; 23:157-162.
5. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
6. Rosenstock J, Park G, Zimmerman J, U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-1142.
7. Schober E, Schoenle E, Van Dyk J, et al. Comparative trial between insulin glargine and NPH insulin in children and adolescents with Type 1 diabetes. Diabetes Care 2001; 24: 2005-2006.
8. Porcellati F, Rossetti P, Fanelli C, et al. Glargine vs NPH as basal insulin in intensive treatment of type 1 diabetes mellitus given lispro at meals: one year comparison (Abstract). Diabetes 2002; 51: A217.
9. Schober E, Schoenle E, Van Dyk J, et al, Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescent with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15: 369-376.
10. Ratner RE, Hirsch IB, Neifing JL, et al, U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-643.
11. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabetic Med 2001; 18: 619-625.
12. Chatterjee S, Gallen IW, Sandler L. 2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications. Diabetes Care 1999; 22: 1226-1227.
13. Gallen IW. Innovative use of computerized scanning equipment to establish and maintain a hospital clinic diabetes database. Diabetes Today 1999; 2: 13-16.
14. Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999; 8: 79-91.
15. Bradley C. The Well-being Questionaire. In Handbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practice. Bradley C (ed). Chur, Switzerland: Harwood Academic Publishers, 1994.
16. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabetic Med 1990; 7: 445-451.
17. Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43: 1378-1389.